



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,110	02/24/2005	Qishou Xu	CU-4057 BWH	3549
26530	7590	08/23/2010	EXAMINER	
LADAS & PARRY LLP 224 SOUTH MICHIGAN AVENUE SUITE 1600 CHICAGO, IL 60604			GOON, SCARLETT Y	
ART UNIT	PAPER NUMBER		1623	
MAIL DATE	DELIVERY MODE			
08/23/2010	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/522,110	XU ET AL.	
	Examiner SCARLETT GOON	Art Unit 1623	

All Participants:

(1) SCARLETT GOON.

Status of Application: pending

(3) _____.

(2) Ms. Zareefa Flener, Applicants' atty.

(4) _____.

Date of Interview: 17 August 2010**Time:** 3:16 pm**Type of Interview:**

- Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description: .

Part I.

Rejection(s) discussed:

none

Claims discussed:

see below

Prior art documents discussed:

*none***Part II.****SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

Ms. Flener was contacted to discuss potential allowable subject matter. The Examiner indicated that the Declaration filed by Applicants on 21 July 2010 suggested unexpected results in which the 5-laurate ester of riboflavin was significantly less cytotoxic than the corresponding longer and shorter ester derivatives. However, the Examiner indicated that the data for unexpected results was not commensurate in scope with the claims. The Examiner queried whether Applicants would be able to provide similar data of potential unexpected results that were commensurate in scope with the claims. Ms. Flener indicated she would discuss the request with Applicants. Although not specifically discussed in the interview with Ms. Flener, the data provided by Applicants for showing unexpected results tested 120 μmol/L and 240 μmol/L of the monoester compounds. However, the claims are drawn to compositions comprising 50-150 mg of the laurate monoester in 0.1-1 mL of ethyl oleate and 0-1 mL of camellia oil. The lowest concentration claimed is therefore 50 mg of the laurate monoester in 0.1 mL of ethyl oleate, a concentration of 890 mM.

Part III.

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/SCARLETT GOON/
 Examiner, Art Unit 1623

(Applicant/Applicant's Representative Signature – if appropriate)